Positron emission tomography oncology research in the UK: A comparison with USA and Europe

Nuclear Medicine Communications

Volumn 33, Issue 4, 2012, Pages 341-348

  Fleming, Ian N ^a,b   Regel, Sabine J ^b,c   Pike, Lucy C ^b,c   Marsden, Paul K ^b,c   Gilbert, Fiona J ^a,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cancer; clinical trials; fluorodeoxyglucose; oncology; PET; radiotracers

Indexed keywords

1 (2' DEOXY 2' FLUORO BETA DEXTRO ARABINOFURANOSYL)THYMINE F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 16 [F 18]FLUORO 17 OESTRADIOL F 18; 3 [F 18]FLUORO 2 [4[(2 NITRO 1H IMADAZOLE 1 YL)METHYL] 1 H 1,2,3, TRIAZOL 1 YL)PROPAN 1 OL F 18; 3' FLUOROTHYMIDINE F 18; 3,4 DIHYDROXY 6 F 18 FLUORO PHENYLALANINE F 18; [2 (5 FLUORO PENTYL) 2 METHYL MALONIC ACID] F 18; BEVACIZUMAB ZR 89; CHOLINE C 11; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; FLUCCICLATIDE F 18; FLUCICLATIDE F 18; FLUORINE 18; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; GALACTO RDG PEPTIDE F 18; METHIONINE C 11; METOMIDATE C 11; O (2 [F 18] FLUOROETHYL)TYROSINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADRENAL CANCER; BELGIUM; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER STAGING; COLON CANCER; DENMARK; ESOPHAGUS CANCER; EUROPE; FRANCE; GEOGRAPHY; GERMANY; HEAD AND NECK CANCER; HEALTH CARE FACILITY; HUMAN; ITALY; KIDNEY CANCER; LARGE CELL LYMPHOMA; LUNG CANCER; LYMPHOMA; MELANOMA; NETHERLANDS; OVARY; PANCREAS CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RECTUM CANCER; REVIEW; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES;

EUROPE; GREAT BRITAIN; HUMANS; MEDICAL ONCOLOGY; MULTICENTER STUDIES AS TOPIC; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RESEARCH; UNITED STATES;

EID: 84858224988     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283500b6d     Document Type: Review

References (27)

1. Gilbert FJ, Fleming IN, Marsden PK. Beyond 18F-fluorodeoxyglucose: Making the next generation of PET radiotracers available for oncology research in the UK. Nucl Med Commun 2011; 32:1-3.
2. A framework for PET research in the UK, 2007. Available at www.ncri.org.uk/publications/reports/2007. [Accessed 6 January 2011].
3. Location of PET scanners in UK. 2010. Available at www.ncri-pet.org/ quicklinks/PET scanner locations in UK. [Accessed 17 January 2011].
4. CRUK. Cancer Imaging Initiatives, 2007. Available at http://science. cancerresearchuk.org/research/how-we-deliver-our-research/others/ strategic-initiatives/. [Accessed 6 January 2011].
5. Early phase PET research in the UK: consensus opinion on prioritised research areas in oncology, 2009. Available at www.ncri-pet.org.uk/resources/ early phase research. [Accessed 6 January 2011].
6. PET & Molecular Imaging tracking growth in Europe. 2010. Available at www.medicaloptions.co.uk/assets/PETproposal10e.pdf. [Accessed 6 October 2011].
7. PET-CT likely demand. 2009. Available at http://www.bnms.org.uk/uk-pet/ ctadvisory-board/pet-ct-likely-demand.html. [Accessed 6 October 2011].
8. Kotzerke J, Oehme L, Lindner O, Hellwig D, Bartenstein P, Baum RP, et al. Positron emission tomography 2008 in Germany: results of the query and current status. Nuklearmedizin 2010; 49:58-64.
9. Bedford M, Maisey MN. Requirements for clinical PET: comparisons within Europe. Eur J Nucl Med Mol Imaging 2004; 31:208-221. (Pubitemid 38173696)
10. FDG PET scans in USA in 2010. June 6th, 2011. Available at www.cellpointweb.com/2011-SNM-Final.pdf. [Accessed 6 October 2011].
11. UK PET trials database. Available at www.ncri-pet/resources/databases/PET trials database. [Accessed 01/06 2011].
12. Murphy PS, Bergström M. Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective. Curr Pharm Des 2009; 15:957-965.
13. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586. (Pubitemid 350002966)
14. Anderson H, Singh N, Miles K. Tumour response evaluation with fluorodeoxyglucose positron emission tomography: research technique or clinical tool? Cancer Imaging 2010; 10:S68-S72.
15. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
16. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50:122S-150S.
17. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyögg J. Economic evaluation of PET and PET/CT in oncology: Evidence and methodologic approaches. J Nucl Med 2010; 51:401-412.
18. Fleming IN, Gilbert FJ, Miles KA, Cameron D. Opportunities for PET to deliver clinical benefit in cancer: Breast cancer as a paradigm. Cancer Imaging 2010; 10:144-152.
19. Gould P. Medical isotope shortage reaches crisis level. Nature 2009; 460:312-313.
20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
21. Innovative Medicines Initiative - Call for imaging biomarkers in cancer. November/27th, 2009. Available at http://www.epda.eu.com/news-archive/2009/2009- 11-27-imi/. [Accessed 7 January 2011].
22. How to increase availability of non-fluorodeoxyglucose radiotracers for PET research in the UK, 2010. Available at www.ncri-pet.org.uk/resources/early phase research. [Accessed 6 January 2011].
23. Overview of oncology PET radiotracers available in the UK. 12th July 2010, 2010. Available at http://www.ncri-pet.org.uk/. [Accessed 4 May 2011].
24. FES Transfer Agreement, 2011. Available at http://imaging.cancer.gov/ programsandresources/fes-transfer-agreement. [Accessed 6 October 2011].
25. Centralized Imaging Biomarker INDs. 6th May, 2011. Available at http://interactive.snm.org/index.cfm?PageID=8819&RPID=1977. [Accessed 6 October 2011].
26. FDA Embraces a New Review Process and Approves SNM's Multi-center IND for FLT. February 2nd, 2009. Available at http://interactive.snm.org/index.cfm? PageID=8828. [Accessed 6 October 2011].
27. Fleming IN, Gilbert FJ, Blower PJ. Building PET research collaborations. Nucl Med Commun 2012; 33:1-3.